Longitudinal changes in cell‐mediated immunity after varicella‐zoster virus skin test in the general population; Shozu Herpes Zoster Study: SHEZ study

Varicella‐zoster virus‐specific cell‐mediated immunity has been associated with the onset and severity of herpes zoster (HZ), and the administration of the HZ vaccine enhanced the immunity. However, limited data is available on the duration of cell‐mediated immunity enhancement by soluble antigen of...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 95; no. 1; pp. e28336 - n/a
Main Authors Ikeda, Daisuke, Imano, Hironori, Mori, Yasuko, Asada, Hideo, Yamanishi, Koichi, Okuno, Yoshinobu, Iso, Hiroyasu
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.01.2023
Subjects
Aged
antigen
Antigens
cell‐mediated immunity
Chicken pox
Cohort analysis
Cohort Studies
cohort study
Deactivation
Enzyme-linked immunosorbent assay
general population
Herpes Zoster
Herpesvirus 3, Human
Humans
Humoral immunity
Immunity
Immunity, Cellular
Inoculation
Middle Aged
persistence
Population studies
Prospective Studies
skin test
Skin Tests
Vaccines
Varicella
varicella‐zoster virus
Virology
Viruses
varicella-zoster virus
cohort study
herpes zoster
persistence
antigen
general population
skin test
cell-mediated immunity
Online AccessGet full text

Cover

Abstract Varicella‐zoster virus‐specific cell‐mediated immunity has been associated with the onset and severity of herpes zoster (HZ), and the administration of the HZ vaccine enhanced the immunity. However, limited data is available on the duration of cell‐mediated immunity enhancement by soluble antigen of varicella‐zoster virus (VZV) skin test. A prospective, community‐based cohort study was conducted in Shozu County, Kagawa Prefecture, Japan. Repeated VZV skin tests containing inactivated VZV antigen and blood tests were performed on 365 subjects aged 60 years and older at baseline, 1, 2, and 3 years later. The differential immunity indices of VZV over time for cell‐mediated and humoral immunity were evaluated. VZV skin test reaction and ELISpot counts increased significantly at 1, 2, and 3 years later compared to the baseline. However, humoral immunity indices did not change materially over time. Soluble antigen by VZV skin test enhanced VZV‐specific cell‐mediated immunity, and it persisted for at least 1 year. In addition, the inoculation with inactivated antigens every year by VZV skin test continued to enhance VZV‐specific cell‐mediated immunity after 2 and 3 years.
AbstractList Varicella-zoster virus-specific cell-mediated immunity has been associated with the onset and severity of herpes zoster (HZ), and the administration of the HZ vaccine enhanced the immunity. However, limited data is available on the duration of cell-mediated immunity enhancement by soluble antigen of varicella-zoster virus (VZV) skin test. A prospective, community-based cohort study was conducted in Shozu County, Kagawa Prefecture, Japan. Repeated VZV skin tests containing inactivated VZV antigen and blood tests were performed on 365 subjects aged 60 years and older at baseline, 1, 2, and 3 years later. The differential immunity indices of VZV over time for cell-mediated and humoral immunity were evaluated. VZV skin test reaction and ELISpot counts increased significantly at 1, 2, and 3 years later compared to the baseline. However, humoral immunity indices did not change materially over time. Soluble antigen by VZV skin test enhanced VZV-specific cell-mediated immunity, and it persisted for at least 1 year. In addition, the inoculation with inactivated antigens every year by VZV skin test continued to enhance VZV-specific cell-mediated immunity after 2 and 3 years.Varicella-zoster virus-specific cell-mediated immunity has been associated with the onset and severity of herpes zoster (HZ), and the administration of the HZ vaccine enhanced the immunity. However, limited data is available on the duration of cell-mediated immunity enhancement by soluble antigen of varicella-zoster virus (VZV) skin test. A prospective, community-based cohort study was conducted in Shozu County, Kagawa Prefecture, Japan. Repeated VZV skin tests containing inactivated VZV antigen and blood tests were performed on 365 subjects aged 60 years and older at baseline, 1, 2, and 3 years later. The differential immunity indices of VZV over time for cell-mediated and humoral immunity were evaluated. VZV skin test reaction and ELISpot counts increased significantly at 1, 2, and 3 years later compared to the baseline. However, humoral immunity indices did not change materially over time. Soluble antigen by VZV skin test enhanced VZV-specific cell-mediated immunity, and it persisted for at least 1 year. In addition, the inoculation with inactivated antigens every year by VZV skin test continued to enhance VZV-specific cell-mediated immunity after 2 and 3 years.
Varicella-zoster virus-specific cell-mediated immunity has been associated with the onset and severity of herpes zoster (HZ), and the administration of the HZ vaccine enhanced the immunity. However, limited data is available on the duration of cell-mediated immunity enhancement by soluble antigen of varicella-zoster virus (VZV) skin test. A prospective, community-based cohort study was conducted in Shozu County, Kagawa Prefecture, Japan. Repeated VZV skin tests containing inactivated VZV antigen and blood tests were performed on 365 subjects aged 60 years and older at baseline, 1, 2, and 3 years later. The differential immunity indices of VZV over time for cell-mediated and humoral immunity were evaluated. VZV skin test reaction and ELISpot counts increased significantly at 1, 2, and 3 years later compared to the baseline. However, humoral immunity indices did not change materially over time. Soluble antigen by VZV skin test enhanced VZV-specific cell-mediated immunity, and it persisted for at least 1 year. In addition, the inoculation with inactivated antigens every year by VZV skin test continued to enhance VZV-specific cell-mediated immunity after 2 and 3 years.
Varicella‐zoster virus‐specific cell‐mediated immunity has been associated with the onset and severity of herpes zoster (HZ), and the administration of the HZ vaccine enhanced the immunity. However, limited data is available on the duration of cell‐mediated immunity enhancement by soluble antigen of varicella‐zoster virus (VZV) skin test. A prospective, community‐based cohort study was conducted in Shozu County, Kagawa Prefecture, Japan. Repeated VZV skin tests containing inactivated VZV antigen and blood tests were performed on 365 subjects aged 60 years and older at baseline, 1, 2, and 3 years later. The differential immunity indices of VZV over time for cell‐mediated and humoral immunity were evaluated. VZV skin test reaction and ELISpot counts increased significantly at 1, 2, and 3 years later compared to the baseline. However, humoral immunity indices did not change materially over time. Soluble antigen by VZV skin test enhanced VZV‐specific cell‐mediated immunity, and it persisted for at least 1 year. In addition, the inoculation with inactivated antigens every year by VZV skin test continued to enhance VZV‐specific cell‐mediated immunity after 2 and 3 years.
Author Asada, Hideo
Iso, Hiroyasu
Ikeda, Daisuke
Imano, Hironori
Okuno, Yoshinobu
Yamanishi, Koichi
Mori, Yasuko
Author_xml – sequence: 1
  givenname: Daisuke
  orcidid: 0000-0002-3622-6760
  surname: Ikeda
  fullname: Ikeda, Daisuke
  organization: Osaka University Graduate School of Medicine
– sequence: 2
  givenname: Hironori
  surname: Imano
  fullname: Imano, Hironori
  organization: Kindai University Faculty of Medicine
– sequence: 3
  givenname: Yasuko
  surname: Mori
  fullname: Mori, Yasuko
  organization: Kobe University Graduate School of Medicine
– sequence: 4
  givenname: Hideo
  surname: Asada
  fullname: Asada, Hideo
  organization: Nara Medical University School of Medicine
– sequence: 5
  givenname: Koichi
  surname: Yamanishi
  fullname: Yamanishi, Koichi
  organization: The Research Foundation for Microbial Diseases of Osaka University
– sequence: 6
  givenname: Yoshinobu
  surname: Okuno
  fullname: Okuno, Yoshinobu
  organization: The Research Foundation for Microbial Diseases of Osaka University
– sequence: 7
  givenname: Hiroyasu
  surname: Iso
  fullname: Iso, Hiroyasu
  email: iso@pbhel.med.osaka-u.ac.jp
  organization: Institute of Global Health Policy Research (iGHP), Bureau of International Health Cooperation, National Center for Global Health and Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36418204$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1uEzEUhS1URNPCghdAltjAIq1_ZjwzsEJVS0BBLAIsurGcmTuJw4w9-KcoXfURWPN4PAmeJN1UsLJlfef43nNO0JGxBhB6TskZJYSdb_qbM1ZyLh6hCSWVmFakoEdoQmgmpkLQ_BideL8hhJQVY0_QMRcZLRnJJuj33JqVDrHRRnW4XiuzAo-1wTV03Z-7Xz00WgVosO77aHTYYtUGcPhGOT0iKjG31u-etIse--9JHMCH0SSsAa_AgEvegx1ip4K25i1erO1txDNwQ_rsei9fpCG2b_BidnmN_Xh_ih63qvPw7HCeoq9Xl18uZtP55_cfLt7NpzXP0q6UcwVNvqQVUMgboKUSqikoE5S1TcUaQWrO6qJo6zxrSL1cAhWEp7xYRXib81P0au87OPsjpsllr_1uNwM2eskKXhVZxkSR0JcP0I2NLiU3UoLSskqpJurFgYrLlJ8cnO6V28r71BNwvgdqZ7130Mpah100wSndSUrk2KtMvcpdr0nx-oHi3vRf7MH9p-5g-39Qfvz0ba_4C4XttZo
CitedBy_id crossref_primary_10_1055_a_2243_3308
crossref_primary_10_1002_rmv_2554
Cites_doi 10.1056/NEJMe020138
10.1093/infdis/136.6.784
10.1093/infdis/jiv480
10.1017/S0950268812002671
10.1016/j.jcv.2012.06.008
10.2188/jea.JE20140210
10.1093/cid/ciu918
10.2188/jea.JE20110035
10.1056/NEJMcp1302674
10.1128/CDLI.8.5.871-879.2001
10.4103/ijdvl.IJDVL_1021_16
10.1371/journal.pmed.1001420
10.1093/infdis/jiy514
10.11150/kansenshogakuzasshi.85.161
10.1016/S0264-410X(02)00407-3
10.1016/j.vaccine.2011.11.096
10.1016/S0264-410X(03)00303-7
10.1099/0022-1317-61-2-255
10.1056/NEJMoa1501184
10.1093/aje/kwx245
10.1086/592219
10.1007/s40273-018-0735-1
10.1093/infdis/143.5.684
10.1056/NEJMoa051016
10.1002/jmv.21599
10.1001/archinte.1995.00430150071008
10.1093/cid/cis638
10.1002/jmv.24629
10.1093/infdis/jiw047
10.1016/j.vaccine.2019.09.031
ContentType Journal Article
Copyright 2022 Wiley Periodicals LLC.
Copyright_xml – notice: 2022 Wiley Periodicals LLC.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7TK
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
DOI 10.1002/jmv.28336
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Bacteriology Abstracts (Microbiology B)
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Virology and AIDS Abstracts
Technology Research Database
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

CrossRef
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1096-9071
EndPage n/a
ExternalDocumentID 36418204
10_1002_jmv_28336
JMV28336
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Research Foundation for Microbial Diseases of Osaka University
– fundername: Japanese Ministry of Health, Labour and Welfare for Research on Publicly Essential Drugs and Medical Devices (fiscal year 2008–2010)
  funderid: KHC1102
– fundername: Japanese Ministry of Health, Labour and Welfare for Public‐Private Sector Joint Research on Publicly Essential Drugs (fiscal year 2011–2012)
  funderid: KHC1102
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
31~
33P
3O-
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AI.
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
ECGQY
EJD
ELTNK
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M65
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGB
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V2E
VH1
W8V
W99
WBKPD
WHG
WIB
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XPP
XV2
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7TK
7U9
8FD
C1K
FR3
H94
K9.
M7N
P64
RC3
7X8
ID FETCH-LOGICAL-c3496-133aed5b19e1e5de18a6ad712612fd92d60c32c77fc54d0cbbe16032832903f53
IEDL.DBID DR2
ISSN 0146-6615
1096-9071
IngestDate Fri Jul 11 04:07:48 EDT 2025
Wed Aug 13 00:17:57 EDT 2025
Wed Feb 19 02:24:50 EST 2025
Thu Jul 24 01:54:52 EDT 2025
Thu Apr 24 23:08:09 EDT 2025
Wed Jan 22 16:19:34 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords varicella-zoster virus
cohort study
herpes zoster
persistence
antigen
general population
skin test
cell-mediated immunity
Language English
License 2022 Wiley Periodicals LLC.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3496-133aed5b19e1e5de18a6ad712612fd92d60c32c77fc54d0cbbe16032832903f53
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-3622-6760
PMID 36418204
PQID 2761189820
PQPubID 105515
PageCount 10
ParticipantIDs proquest_miscellaneous_2739744267
proquest_journals_2761189820
pubmed_primary_36418204
crossref_citationtrail_10_1002_jmv_28336
crossref_primary_10_1002_jmv_28336
wiley_primary_10_1002_jmv_28336_JMV28336
PublicationCentury 2000
PublicationDate January 2023
PublicationDateYYYYMMDD 2023-01-01
PublicationDate_xml – month: 01
  year: 2023
  text: January 2023
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: London
PublicationTitle Journal of medical virology
PublicationTitleAlternate J Med Virol
PublicationYear 2023
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2018; 187
2009; 81
2005; 352
2013; 369
2019; 37
1981; 143
2017; 89
2013; 141
2018; 84
1995; 155
2012; 55
2012; 30
2015; 372
2015; 25
2015; 60
2013; 10
1982; 61
2003; 8
2001; 8
2011; 85
2002; 347
2019; 219
2016; 213
2008; 198
2012; 22
1977; 136
2003; 21
e_1_2_10_23_1
e_1_2_10_24_1
e_1_2_10_21_1
e_1_2_10_22_1
e_1_2_10_20_1
e_1_2_10_2_1
e_1_2_10_4_1
e_1_2_10_18_1
e_1_2_10_3_1
e_1_2_10_19_1
e_1_2_10_6_1
e_1_2_10_16_1
e_1_2_10_5_1
e_1_2_10_17_1
e_1_2_10_8_1
e_1_2_10_14_1
e_1_2_10_7_1
e_1_2_10_15_1
e_1_2_10_12_1
e_1_2_10_9_1
e_1_2_10_13_1
e_1_2_10_10_1
e_1_2_10_32_1
e_1_2_10_31_1
e_1_2_10_30_1
Kidd P (e_1_2_10_11_1) 2003; 8
e_1_2_10_29_1
e_1_2_10_27_1
e_1_2_10_28_1
e_1_2_10_25_1
e_1_2_10_26_1
References_xml – volume: 81
  start-page: 2053
  year: 2009
  end-page: 2058
  article-title: Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10‐year survey of 48,388 herpes zoster cases in Miyazaki prefecture
  publication-title: J Med Virol
– volume: 352
  start-page: 2271
  year: 2005
  end-page: 2284
  article-title: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
  publication-title: N Engl J Med
– volume: 37
  start-page: 169
  year: 2019
  end-page: 200
  article-title: Cost‐effectiveness of herpes zoster vaccination: a systematic review
  publication-title: Pharmacoeconomics
– volume: 37
  start-page: 6776
  year: 2019
  end-page: 6781
  article-title: VZV‐specific cell‐mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster‐associated pain: the SHEZ study
  publication-title: Vaccine
– volume: 25
  start-page: 617
  year: 2015
  end-page: 625
  article-title: Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community‐based prospective cohort study: the SHEZ study
  publication-title: J Epidemiol
– volume: 21
  start-page: 3845
  year: 2003
  end-page: 3853
  article-title: Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay
  publication-title: Vaccine
– volume: 213
  start-page: 14
  year: 2016
  end-page: 22
  article-title: Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults
  publication-title: J Infect Dis
– volume: 10
  year: 2013
  article-title: Herpes zoster vaccine effectiveness against incident herpes zoster and post‐herpetic neuralgia in an older US population: a cohort study
  publication-title: PLoS Med
– volume: 84
  start-page: 251
  year: 2018
  end-page: 262
  article-title: Epidemiology, treatment and prevention of herpes zoster: a comprehensive review
  publication-title: Indian J Dermatol Venereol Leprol
– volume: 369
  start-page: 255
  year: 2013
  end-page: 263
  article-title: Herpes zoster
  publication-title: N Engl J Med
– volume: 85
  start-page: 161
  year: 2011
  end-page: 165
  article-title: Varicella vaccine potency and stability during transport and delivery
  publication-title: Kansenshogaku Zasshi
– volume: 347
  start-page: 1962
  year: 2002
  end-page: 1963
  article-title: Varicella vaccine—are two doses better than one?
  publication-title: N Engl J Med
– volume: 141
  start-page: 706
  year: 2013
  end-page: 713
  article-title: Assessment of skin test with varicella‐zoster virus antigen for predicting the risk of herpes zoster
  publication-title: Epidemiol Infect
– volume: 22
  start-page: 167
  year: 2012
  end-page: 174
  article-title: The shozu herpes zoster (SHEZ) study: rationale, design, and description of a prospective cohort study
  publication-title: J Epidemiol
– volume: 187
  start-page: 161
  year: 2018
  end-page: 169
  article-title: Long‐term effectiveness of the live zoster vaccine in preventing shingles: a cohort study
  publication-title: Am J Epidemiol
– volume: 219
  start-page: 335
  year: 2019
  end-page: 338
  article-title: Persistence of varicella‐zoster virus cell‐mediated immunity after the administration of a second dose of live herpes zoster vaccine
  publication-title: J Infect Dis
– volume: 143
  start-page: 684
  year: 1981
  end-page: 692
  article-title: Soluble skin test antigen of varicella‐zoster virus prepared from the fluid of infected cultures
  publication-title: J Infect Dis
– volume: 21
  start-page: 419
  year: 2003
  end-page: 430
  article-title: Memory T cells and vaccines
  publication-title: Vaccine
– volume: 213
  start-page: 1872
  year: 2016
  end-page: 1875
  article-title: Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years
  publication-title: J Infect Dis
– volume: 61
  start-page: 255
  year: 1982
  end-page: 269
  article-title: Polypeptides of varicella‐zoster virus (VZV) and immunological relationship of VZV and herpes simplex virus (HSV)
  publication-title: J Gen Virol
– volume: 89
  start-page: 313
  year: 2017
  end-page: 317
  article-title: Relationship between cell‐mediated immunity to varicella‐zoster virus and aging in subjects from the community‐based Shozu Herpes Zoster Study
  publication-title: J Med Virol
– volume: 155
  start-page: 1605
  year: 1995
  end-page: 1609
  article-title: The incidence of herpes zoster
  publication-title: Arch Intern Med
– volume: 60
  start-page: 900
  year: 2015
  end-page: 909
  article-title: Long‐term persistence of zoster vaccine efficacy
  publication-title: Clin Infect Dis
– volume: 30
  start-page: 904
  year: 2012
  end-page: 910
  article-title: Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age
  publication-title: Vaccine
– volume: 372
  start-page: 2087
  year: 2015
  end-page: 2096
  article-title: Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults
  publication-title: N Engl J Med
– volume: 55
  start-page: 46
  year: 2012
  end-page: 50
  article-title: A community‐based survey of varicella‐zoster virus‐specific immune responses in the elderly
  publication-title: J Clin Virol
– volume: 55
  start-page: 1320
  year: 2012
  end-page: 1328
  article-title: Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short‐term persistence substudy
  publication-title: Clin Infect Dis
– volume: 198
  start-page: 1327
  year: 2008
  end-page: 1333
  article-title: Measurement of Varicella‐Zoster virus (VZV)–specific cell‐mediated immunity: comparison between VZV skin test and interferon‐γ enzyme‐linked immunospot assay
  publication-title: J Infect Dis
– volume: 136
  start-page: 784
  year: 1977
  end-page: 788
  article-title: Diagnostic skin test reactions with varicella virus antigen and clinical application of the test
  publication-title: J Infect Dis
– volume: 8
  start-page: 223
  year: 2003
  end-page: 246
  article-title: Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease
  publication-title: Altern Med Rev
– volume: 8
  start-page: 871
  year: 2001
  end-page: 879
  article-title: Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella zoster virus
  publication-title: Clin Diagn Lab Immunol
– ident: e_1_2_10_26_1
  doi: 10.1056/NEJMe020138
– volume: 8
  start-page: 223
  year: 2003
  ident: e_1_2_10_11_1
  article-title: Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease
  publication-title: Altern Med Rev
– ident: e_1_2_10_14_1
  doi: 10.1093/infdis/136.6.784
– ident: e_1_2_10_28_1
  doi: 10.1093/infdis/jiv480
– ident: e_1_2_10_21_1
  doi: 10.1017/S0950268812002671
– ident: e_1_2_10_22_1
  doi: 10.1016/j.jcv.2012.06.008
– ident: e_1_2_10_24_1
  doi: 10.2188/jea.JE20140210
– ident: e_1_2_10_25_1
  doi: 10.1093/cid/ciu918
– ident: e_1_2_10_12_1
  doi: 10.2188/jea.JE20110035
– ident: e_1_2_10_2_1
  doi: 10.1056/NEJMcp1302674
– ident: e_1_2_10_16_1
  doi: 10.1128/CDLI.8.5.871-879.2001
– ident: e_1_2_10_5_1
  doi: 10.4103/ijdvl.IJDVL_1021_16
– ident: e_1_2_10_8_1
  doi: 10.1371/journal.pmed.1001420
– ident: e_1_2_10_29_1
  doi: 10.1093/infdis/jiy514
– ident: e_1_2_10_20_1
  doi: 10.11150/kansenshogakuzasshi.85.161
– ident: e_1_2_10_30_1
  doi: 10.1016/S0264-410X(02)00407-3
– ident: e_1_2_10_27_1
  doi: 10.1016/j.vaccine.2011.11.096
– ident: e_1_2_10_18_1
  doi: 10.1016/S0264-410X(03)00303-7
– ident: e_1_2_10_19_1
  doi: 10.1099/0022-1317-61-2-255
– ident: e_1_2_10_31_1
  doi: 10.1056/NEJMoa1501184
– ident: e_1_2_10_10_1
  doi: 10.1093/aje/kwx245
– ident: e_1_2_10_17_1
  doi: 10.1086/592219
– ident: e_1_2_10_32_1
  doi: 10.1007/s40273-018-0735-1
– ident: e_1_2_10_15_1
  doi: 10.1093/infdis/143.5.684
– ident: e_1_2_10_6_1
  doi: 10.1056/NEJMoa051016
– ident: e_1_2_10_4_1
  doi: 10.1002/jmv.21599
– ident: e_1_2_10_3_1
  doi: 10.1001/archinte.1995.00430150071008
– ident: e_1_2_10_7_1
  doi: 10.1093/cid/cis638
– ident: e_1_2_10_23_1
  doi: 10.1002/jmv.24629
– ident: e_1_2_10_9_1
  doi: 10.1093/infdis/jiw047
– ident: e_1_2_10_13_1
  doi: 10.1016/j.vaccine.2019.09.031
SSID ssj0008922
Score 2.3864465
Snippet Varicella‐zoster virus‐specific cell‐mediated immunity has been associated with the onset and severity of herpes zoster (HZ), and the administration of the HZ...
Varicella-zoster virus-specific cell-mediated immunity has been associated with the onset and severity of herpes zoster (HZ), and the administration of the HZ...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e28336
SubjectTerms Aged
antigen
Antigens
cell‐mediated immunity
Chicken pox
Cohort analysis
Cohort Studies
cohort study
Deactivation
Enzyme-linked immunosorbent assay
general population
Herpes Zoster
Herpesvirus 3, Human
Humans
Humoral immunity
Immunity
Immunity, Cellular
Inoculation
Middle Aged
persistence
Population studies
Prospective Studies
skin test
Skin Tests
Vaccines
Varicella
varicella‐zoster virus
Virology
Viruses
Title Longitudinal changes in cell‐mediated immunity after varicella‐zoster virus skin test in the general population; Shozu Herpes Zoster Study: SHEZ study
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjmv.28336
https://www.ncbi.nlm.nih.gov/pubmed/36418204
https://www.proquest.com/docview/2761189820
https://www.proquest.com/docview/2739744267
Volume 95
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHiouvB8LBRnEgUu2iR95tKcKtVpVLAdKUVUhRY7tlKWQXW2SSt0TP4EzP6-_hBk7SVUeEuIWJePYcWY8nx_zDSEvs9BILlgUKBOGgShjHWSJ4oEC7ShFXCoWYrzz9G08ORIHx_J4jez0sTCeH2JYcEPLcOM1Grgq6q0r0tDPX8_H4Bs50m3jWS0ERO-uqKPSzO8gwEgQgA-SPatQyLaGktd90W8A8zpedQ5n_xb52DfVnzM5G7dNMdarX1gc__NbbpObHRClu15z7pA1W90lG9Nuq_0e-fFmjqmMWoNps6iPD67prKK41H_57bsLOQG4SmcuwqS5oC7dOD1XSFMEygUyK4wggVuzZVvT-gwKA7Bt8CUAO-mpZ7ymiyGH2A49_DRftXRilwuo7MQXx6OOF9v0cLJ3Qh0b7n1ytL_3_vUk6BI5BBr56AOYBytrZBFlNrLS2ChVsTJJhPRlpcmYiUPNmU6SUkthQl0UFrNfYxalLOSl5A_IejWv7CNCOWfSqEJwXsCkvjSAb1ItZBpJDciTpSPyqv-lue5YzjHZxpfc8zOzHPo6d309Ii8G0YWn9viT0GavF3ln3XXOkhjmZRmApxF5PjwGu3TdW9l5izKA9ATgn2REHnp9GmrhsUDefAGNdVrx9-rzg-kHd_H430WfkBsMkJhfJ9ok682ytU8BOTXFM2ciPwFmCRdx
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLVKkYAN78dAAYNYsMk08SMPYIOgVSgzXdAWVZWqKLEdGAqZ0UxSqbPiE1jzeXwJ99pJqvKQELsouY4d59742M49h5Ania8lFyzwcu37nihD5SVRzr0cvKMUYZkzH_Odx9thuie29uX-CnnR5cI4foh-wQ0jw36vMcBxQXr9lDX005fjIQyOPDxHzqOiNzLnv353Sh4VJ24PAb4FHoxCsuMV8tl6X_TsaPQbxDyLWO2Qs3mFHHaNdX-aHA2buhiq5S88jv_7NFfJ5RaL0pfOea6RFVNdJxfG7W77DfJ9NEU1o0ajchZ1KcILOqkorvb_-PrNZp0AYqUTm2RSn1CrOE6Pc2QqAv8CmyUmkcCpybxZ0MURFAZsW-NNAHnSD470ms56GbHndOfjdNnQ1MxnUNmBK45_O548ozvpxgG1hLg3yd7mxu6r1Gu1HDyFlPQeTIVzo2URJCYwUpsgzsNcRwEymJU6YTr0FWcqikolhfZVURgUwEYhpcTnpeS3yGo1rcwdQjlnUueF4LyAeX2pAeLESsg4kArAJ4sH5Gn3TjPVEp2j3sbnzFE0swz6OrN9PSCPe9OZY_f4k9Fa5xhZG-CLjEUhTM0SwE8D8qi_DKFpu7cy0wZtAOwJgEDRgNx2DtXXwkOB1PkCGmvd4u_VZ1vj9_bg7r-bPiQX093xKBu92X57j1xiAMzcstEaWa3njbkPQKouHth4-Qm_JhuN
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL0qRarYlPLsQAGDWLDJNPEjj3aFaEdD6VSIUlRVSFFiOzAUMqOZpFJnxSew5vP4Eq7tJFV5SIhdlFzHiXOvfez4ngPwNPGVYJwGXqZ83-NFKL0kypiXoXcUPCwy6pt859FBODzie8fieAm221wYxw_RLbiZyLD9tQnwqSo2L0hDP3056-PYyMIrcJWHfmJ0G3beXHBHxYn7hYBdgYeDkGhphXy62RW9PBj9hjAvA1Y74gyuw_v2Wd1Gk9N-XeV9ufiFxvE_X2YNVhskSp4717kBS7q8CSuj5l_7Lfi-PzFaRrUyulnEJQjPybgkZq3_x9dvNucE8SoZ2xST6pxYvXFylhmeIvQutFmYFBI8NZ7VczI_xcKIbCtzE8Sd5IOjvCbTTkRsmxx-nCxqMtSzKVZ24oqbvY7nW-RwuHtCLB3ubTga7L59MfQaJQdPGkJ6DyfCmVYiDxIdaKF0EGdhpqLA8JcVKqEq9CWjMooKKbjyZZ5rI39tZJQSnxWC3YHlclLqdSCMUaGynDOW46y-UAhwYslFHAiJ0JPGPXjWftJUNjTnRm3jc-oImmmKbZ3atu7Bk8506rg9_mS00fpF2oT3PKVRiBOzBNFTDx53lzEwbfOWelIbG4R6HAFQ1IO7zp-6WljIDXE-x4e1XvH36tO90Tt7cO_fTR_ByuudQbr_8uDVfbhGEZW5NaMNWK5mtX6AKKrKH9po-QlkAho8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Longitudinal+changes+in+cell-mediated+immunity+after+varicella-zoster+virus+skin+test+in+the+general+population%3B+Shozu+Herpes+Zoster+Study%3A+SHEZ+study&rft.jtitle=Journal+of+medical+virology&rft.au=Ikeda%2C+Daisuke&rft.au=Imano%2C+Hironori&rft.au=Mori%2C+Yasuko&rft.au=Asada%2C+Hideo&rft.date=2023-01-01&rft.issn=1096-9071&rft.eissn=1096-9071&rft.volume=95&rft.issue=1&rft.spage=e28336&rft_id=info:doi/10.1002%2Fjmv.28336&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0146-6615&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0146-6615&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0146-6615&client=summon